Polycystic Ovary Syndrome: A Common Reproductive and Metabolic Disorder Necessitating Early Recognition and Treatment

Primary Care - Clinics in Office Practice

Volumn 34, Issue 4, 2007, Pages 761-789

  Futterweit, Walter ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIFENE; CYANOCOBALAMIN; DROSPIRENONE; ESTROGEN; ETHINYLESTRADIOL; FOLIC ACID; FOLLITROPIN; GESTAGEN; INSULIN SENSITIZING AGENT; METFORMIN; ORAL CONTRACEPTIVE AGENT; PIOGLITAZONE; ROSIGLITAZONE; SPIRONOLACTONE;

ACANTHOSIS NIGRICANS; ACNE; ALOPECIA; BODY FAT DISTRIBUTION; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ECHOGRAPHY; ETHNIC GROUP; HEALTH CARE PERSONNEL; HEART INFARCTION; HIRSUTISM; HORMONAL THERAPY; HUMAN; INSULIN RESISTANCE; LABORATORY TEST; LIFESTYLE; MENSTRUAL CYCLE; MENSTRUATION DISORDER; METABOLIC DISORDER; MONOTHERAPY; OBESITY; OVARY CYST; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SLEEP APNEA SYNDROME; TREATMENT OUTCOME;

ACNE VULGARIS; ALOPECIA; CORONARY ARTERY DISEASE; ENDOMETRIAL NEOPLASMS; FEMALE; HIRSUTISM; HUMANS; POLYCYSTIC OVARY SYNDROME; RISK FACTORS; TIME FACTORS;

EID: 36549040041     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2007.07.004     Document Type: Review

References (95)

1. Azziz R., Woods K.S., Reyna R., et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89 6 (2004) 2745-2749
2. Knochenhauer E.S., Key T.J., Kahsar-Miller M., et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83 9 (1998) 3078-3082
3. Ehrmann D.A., Barnes R.B., Rosenfield R.L., et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22 1 (1999) 141-146
4. Legro R.S., Kunselman A.R., Dodson W.C., et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84 1 (1999) 165-169
5. Waldstreicher J., Santoro N.F., Hall J.E., et al. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovary disease: indirect evidence for partial gonadotroph desensitization. J Clin Endocrinol Metab 66 (1988) 165-172
6. Nelson V.L., Qin K.N., Rosenfield R.L., et al. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 86 (2001) 5925-5933
7. Ehrmann D.A. Polycystic ovary syndrome. N Engl J Med 352 (2005) 1223-1236
8. The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Work-shop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81 1 (2004) 19-25
9. Azziz R., Carmina E., Dewailly D., et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 91 11 (2006) 4237-4245
10. Futterweit W. Clinical features of polycystic ovarian disease. In: Futterweit W. (Ed). Polycystic ovarian disease (1984), Springer-Verlag, New York 83-96
11. Azziz R., Sanchez L.A., Knochenhauer E.S., et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 89 2 (2004) 453-462
12. Carmina E. Prevalence of idiopathic hirsutism. Eur J Endocrinol 139 4 (1998) 421-423
13. Hatch R., Rosenfield R.L., Kim M.H., et al. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 140 8 (1981) 815-830
14. Rosenfield R.L., and Deplewski D. Role of androgens in the developmental biology of the pilosebaceous unit. Am J Med 98 Suppl 1A (1995) 80S-88S
15. Rosenfield R.L. Hirsutism. N Engl J Med 353 24 (2005) 2578-2588
16. Borgia F., Cannavo S., Guarneri F., et al. Correlation between endocrinological parameters and acne severity in adult women with acne. Acta Derm Venereol 84 3 (2004) 201-204
17. Timpatanapong P., and Rojanasakul A. Hormonal profiles and prevalence of polycystic ovary syndrome in women with acne. J Dermatol 24 4 (1997) 223-229
18. Lucky A.W., McGuire J., Rosenfield R.L., et al. Plasma androgens in acne vulgaris. J Invest Dermatol 81 1 (1983) 70-74
19. Peserico A., Angeloni G., Bertoli P., et al. Prevalence of polycystic ovaries in women with acne. Arch Dermatol Res 281 7 (1989) 502-503
20. Futterweit W., Dunaif A., Yeh H.-C., et al. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. J Am Acad Dermatol 19 5 Pt 1 (1988) 831-836
21. Cela E., Robertson C., Rush K., et al. Prevalence of polycystic ovaries in women with androgenic alopecia. Eur J Endocrinol 149 5 (2004) 439-442
22. Redmond G.P. Clinical evaluation of the woman with an androgenic disorder. In: Redmond G.P. (Ed). Androgenic disorders (1995), Raven Press, New York 1-20
23. Unger J. Diagnosing and managing the metabolic syndrome in adults, children and adolescents. In: Unger J. (Ed). Diabetes management in primary care (2007), Lippincott, Williams and Wilkins, Philadelphia 43-87
24. Carey D.G., Jenkins A.B., Campbell L.V., et al. Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 45 5 (1996) 633-638
25. DeNino W.F., Tchernof A., Dionne I.J., et al. Contribution of abdominal adiposity to age-related differences in insulin sensitivity and plasma lipids in healthy nonobese women. Diabetes Care 24 5 (2001) 925-932
26. National Heart, Lung, and Blood Institute, National Institutes of Health (2000). The practical guide: identification, evaluation, and treatment of overweight and obesity in adults (NIH Publication No. 00-4084). Available at: http://www.nhlbi.nih.gov/guidelines/obesity/prctgd_c.pdf.
27. Fogel R.B., Malhotra A., Pillar G., et al. Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 86 3 (2001) 1175-1180
28. Vgontzas A.N., Legro R.S., Bixler E.O., et al. Polycystic ovary syndrome is associated with obstructive sleep apnea syndrome and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab 86 2 (2001) 517-520
29. American Academy of Sleep Medicine. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measured techniques in clinical research. The Report of an American Academy of Sleep Medicine Taskforce. Sleep 22 2 (1999) 667-689
30. Tasali E., Van Cauter E., and Ehrmann D.A. Relationships between sleep disordered breathing and glucose metabolism in polycystic ovary syndrome. J Clin Endocrinol Metab 91 1 (2006) 26-42
31. Hermanns-Le T., Scheen A., and Pierard G.E. Acanthosis nigricans associated with insulin resistance: pathophysiology and management. Am J Clin Dermatol 5 3 (2004) 199-220
32. Dunaif A., Green G., Phelps R.G., et al. Acanthosis nigricans, insulin action, and hyperandrogenism: clinical, histological, and biochemical findings. J Clin Endocrinol Metab 73 3 (1991) 590-595
33. Polson D.W., Adams J., Wadsworth J., et al. Polycystic ovaries: a common finding in normal women. Lancet 1 8590 (1988) 870-872
34. Yeh H.C., Futterweit W., and Thornton J.C. Polycystic ovarian disease: US features in 104 patients. Radiology 163 1 (1987) 111-116
35. Dewailly D., Ardaens Y., and Robert Y. Ultrasound for the evaluation of PCOS. In: Azziz A., Nestler J.E., and Dewailly D. (Eds). Androgen excess disorders in women (1997), Lippencott-Raven Publishers, Philadelphia 269-278
36. Futterweit W., Scher J., Nunez A.E., et al. A case of bilateral dermoid cysts, insulin resistance, and polycystic ovarian disease: association of ovarian tumors with polycystic ovaries with review of the literature. Mt Sinai J Med 50 3 (1983) 251-255
37. Gambarin-Gelwan M., Kinkhabwala S.V., Schiano T.D., et al. Prevalence of nonalcoholic liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol 5 (2007) 496-501
38. Marchesini G., Brizi M., Morselli-Labate A.M., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107 5 (1999) 450-455
39. Conn J.J., Jacobs H.S., and Conway G.S. The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clin Endocrinol (Oxf) 52 1 (2000) 81-86
40. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 17 (2005) 2735-2752
41. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106 25 (2002) 3143-3421
42. US Department of Health and Human Services (DHHS). National Center for Health Statistics. Third National Health and Nutrition Examination Survey. (NHANES III), 1988-1994 (1996), Center for Disease Control and Prevention, Hyattsville (MD)
43. Einhorn D., Reaven G.M., Cobin R.H., et al. American College of endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9 3 (2003) 237-252
44. Dunaif A., Green G., Futterweit W., et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38 9 (1989) 1165-1174
45. Futterweit W., and Deligdisch L. Histopathological effects of exogenously administered testos terone in 19 female to male transsexuals. J Clin Endocrinol Metab 62 (1986) 16-21
46. Diamanti-Kandarakis E., Kouli C., Alexandraki K., et al. Failure of mathmatical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 3 (2004) 1273-1276
47. Laws A., and Reaven G.M. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Intern Med 231 (1992) 25-30
48. American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee. American Association clinical position statement on mMetabolic and cardiovascular consequences of polycystic ovary syndrome. Endocr Pract 11 2 (2005) 126-134
49. Legro R.S., Gnatuk C.L., Kunselman A.R., et al. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 90 6 (2005) 3236-3242
50. Holte J., Bergh T., Berne C., et al. Serum lipoprotein lipid profile in women with the poly-cystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. Clin Endocrinol (Oxf) 41 (1994) 463-471
51. Robinson S., Henderson A.D., Gelding S.V., et al. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol (Oxf) 44 (1996) 277-284
52. Wild S., Pierpoint T., Jacobs H., et al. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil (Camb) 3 (2000) 101-105
53. Christian R.C., Dumesic D.A., Behrenbeck T., et al. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 2562-2580
54. Atiomo W.U., Bates S.A., Condon J.E., et al. The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril 69 (1998) 236-241
55. Dahlgren E., Janson P.O., Johansson S., et al. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 71 8 (1992) 599-604
56. Birdsall M.A., Farquhar C.M., White H.D., et al. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 126 1 (1997) 32-35
57. Solomon C.G., Hu F.B., Dunaif A., et al. Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA 286 19 (2001) 2421-2426
58. Solomon C.G., Hu F.B., and Dunaif A. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 87 (2002) 2013-2017
59. Balen A. Polycystic ovary syndrome and cancer. Hum Reprod Update 7 (2001) 522-525
60. Gu K., Cowie C.C., and Harris M.I. Diabetes and decline in heart disease mortality in US adults. JAMA 281 (1999) 1291-1297
61. American Diabetes Association clinical practice recommendations 2007. Diabetes Care 30 Suppl 1 (2007) S7-S8
62. Kiddy D.S., Hamilton-Fairly D., Bush A., et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 36 1 (1992) 105-111
63. Pasquali R., Antenucci D., Casimirri F., et al. Clinical and hormonal characteristics of obese and amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 68 1 (1989) 173-189
64. Holte J., Bergh T., Berne C., et al. Restored insulin sensitivity but persistently early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 80 9 (1995) 2586-2593
65. Rittmaster R.S. Medical treatment of androgen-dependent hirsutism. J Clin Endocrinol Metab 80 9 (1995) 2559-2563
66. Kuhl H. Comparitive pharmacology of newer progestogens. Drugs 51 (1996) 188-215
67. Guido M., Romualdi D., and Giuliani M. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 89 (2004) 2817-2823
68. Sherif K. Benefits and risks of oral contraceptives. Am J Obstet Gynecol 180 6 Pt 2 (1999) S343-S348
69. Chasan-Taber L., Willett W.C., Stampfer M.J., et al. A prospective study of oral contraceptives and NIDDM among US women. Diabetes Care 20 5 (1997) 330-335
70. Rimm E.B., Manson J.E., Stampfer M.J., et al. Oral contraceptive use and risk of type 2 diabetes mellitus in a large prospective study of women. Diabetologia 35 10 (1992) 967-972
71. Godsland I.F. The influence of female sex steroids on glucose metabolism and insulin action. J Intern Med Suppl 738 (1996) 1-60
72. Diamanti-Kandarakis E., Baillargeon J.P., Iuorno M.J., et al. A modern medical quandary: polycystic ovary syndrome, insulin resistance and oral contraceptive pills. J Clin Endocrinol Metab 88 5 (2003) 1927-1932
73. Baillargeon J.P., McClish D.K., Essah P.A., et al. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 90 7 (2005) 3863-3870
74. Lord J.M., Flight I.H.K., and Norman R.J. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 3 (2003) CD003053
75. Glueck C.J., Wang P., Goldenberg N., et al. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 17 (2002) 2858-2864
76. Baillargeon J.P., Iuorno M.J., and Nestler J.E. Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol 46 2 (2003) 325-340
77. Jakubowicz D.J., Iuomo M.J., Jakubowicz S., et al. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 87 2 (2002) 524-529
78. Glueck C.J., Phillips H., Cameron D., et al. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first trimester spontaneous abortion: a pilot study. Fertil Steril 75 1 (2001) 46-52
79. Nestler J.E. Should patients with polycystic ovary syndrome be treated with metformin?: an enthusiastic endorsement. Human Reprod 17 8 (2002) 1950-1953
80. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 6 (2002) 393-403
81. Mitwally M.F., Witchel S.F., and Casper R.F. Troglitazone: a possible modulator of ovarian steroidogenesis. J Soc Gynecol Investig 9 (2002) 163-167
82. Belli S.H., Graffigna M.N., Oneto A., et al. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with poly-cystic ovary syndrome. Fertil Steril 81 (2004) 624-629
83. Romualdi D., Guido M., and Ciampelli M. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsuinaemic obese patients with polycystic ovary syndrome. Hum Reprod 18 (2003) 1210-1218
84. Buchanan T.A., Xiang A.H., Peters R.K., et al. Preservation of pancreatic b-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51 9 (2002) 2796-2803
85. Bloomgarden Z.T. Thiazolidinediones. Diabetes Care 28 2 (2006) 488-493
86. Spritzer P.M., Lisboa K.O., Mattiello S., et al. Spironolactone as a single agent for longterm therapy of hirsute patients. Clin Endocrinol (Oxf) 52 (2000) 587-594
87. Lakryc E.C., Motta E.L., Soares Jr. J.M., et al. The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism. Gynecol Endocrinol 17 1 (2003) 57-63
88. Venturoli S., Marescalchi O., Colombo F.M., et al. A prospective randomized trial comparing low-dose flutamide, finasteride, ketoconazole and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab 84 4 (1999) 1304-1310
89. Tartagni M., Schonauer M.M., Cicinelli E., et al. Intermittent low-dose finasteride is as affective as daily administration for the treatment of hirsute women. Fertil Steril 82 3 (2004) 752-756
90. Carmina E., and Lobo R.A. Treatment of hyperandrogenic alopecia in women. Fertil Steril 79 1 (2003) 91-95
91. Olszewska M., and Rudnicka L. Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol 4 5 (2005) 637-640
92. Cusan L., Dupont A., Gomez J.L., et al. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril 61 2 (1994) 281-287
93. Ciotta L., Cianci A., Marletta E., et al. Treatment of hirsutism with flutamide and a low-dosage oral contraceptive in polycystic ovarian disease patients. Fertil Steril 62 6 (1994) 1129-1135
94. Norman R.J. Metformin-comparison with other therapies in ovulation induction in polycystic ovary syndrome. J Clin Endocrinol Metab 89 10 (2004) 4797-4800
95. Rittmaster R.S. Gonadotropin-releasing hormone (GnRH) agonists and estrogen/progestin replacement for the treatment of hirsutism: evaluating the results. J Clin Endocrinol Metab 80 12 (1995) 3403-3405